Overall and progression free survival, treated metastasis control for all 361 oligometastatic patients treated with ablative radiotherapy.
- Julian C. Hong (5094857)
- Diandra N. Ayala-Peacock (5094854)
- Jason Lee (1330398)
- A. William Blackstock (5094848)
- Paul Okunieff (302426)
- Max W. Sung (155300)
- Ralph R. Weichselbaum (113294)
- Johnny Kao (154784)
- James J. Urbanic (5094845)
- Michael T. Milano (5094851)
- Steven J. Chmura (113286)
- Joseph K. Salama (192313)
Publication date
April 2018
DOIAbstract
<p>Median survival was 47.1 months and 3-year survival was 56% (A). Median progression-free survival was 10.1 months and 3-year progression-free survival was 24% (B). Median treated metastasis control was not reached and 3-year TMC was 72% (C).</p
Add to ORKG